Ernexa Therapeutics Inc. (ERNA)

NASDAQ: ERNA · Real-Time Price · USD
0.1938
+0.0096 (5.21%)
Apr 23, 2025, 4:00 PM EDT - Market closed
5.21%
Market Cap 10.13M
Revenue (ttm) 582,000
Net Income (ttm) -44.56M
Shares Out 52.24M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 153,017
Open 0.1910
Previous Close 0.1842
Day's Range 0.1883 - 0.1960
52-Week Range 0.1500 - 2.6300
Beta 7.37
Analysts n/a
Price Target n/a
Earnings Date May 13, 2025

About ERNA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ERNA
Full Company Profile

Financial Performance

In 2024, Ernexa Therapeutics's revenue was $582,000, an increase of 755.88% compared to the previous year's $68,000. Losses were -$44.56 million, 105.5% more than in 2023.

Financial Statements

News

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer Conference attendees will get first look at new data that su...

1 day ago - GlobeNewsWire

Ernexa Therapeutics Closes New Funding Round

Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer Comes on the heels of company's rebranding and new strategic direction, advancing i...

20 days ago - GlobeNewsWire

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchy...

2 months ago - GlobeNewsWire

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

New data from proof-of-concept study provides roadmap for treatment of ovarian cancer.

3 months ago - GlobeNewsWire

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna's lead indication in ovarian cancer World-renowned researcher brings expertise in obstetr...

3 months ago - GlobeNewsWire

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listin...

5 months ago - GlobeNewsWire

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced the successful completion of a comprehensive financial restructu...

6 months ago - GlobeNewsWire

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license an...

6 months ago - GlobeNewsWire

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic...

1 year ago - GlobeNewsWire

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a preclinical-stage biopharmaceutical company, committed to realizing the poten...

1 year ago - GlobeNewsWire

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

1 year ago - GlobeNewsWire

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

1 year ago - GlobeNewsWire

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

1 year ago - GlobeNewsWire

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engin...

1 year ago - GlobeNewsWire

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

1 year ago - GlobeNewsWire

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications

1 year ago - GlobeNewsWire

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engi...

1 year ago - GlobeNewsWire

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engine...

1 year ago - GlobeNewsWire

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell enginee...

2 years ago - GlobeNewsWire

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease

2 years ago - GlobeNewsWire

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion

2 years ago - GlobeNewsWire

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors

2 years ago - GlobeNewsWire

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engin...

2 years ago - GlobeNewsWire

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it advances its mRNA cell engineering platform

2 years ago - GlobeNewsWire

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications

2 years ago - GlobeNewsWire